BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the efficacy of Intravenous (IV) BG00010
(Neublastin) in improving pain in painful lumbar radiculopathy participants when administered
3 times per week for 1 week.
The secondary objectives of this study in this study population are as follows: To explore
the duration of the effect of BG00010 in improving pain; To explore the dose response curve
on pain reduction; To assess the safety and tolerability of BG00010; To assess the serum
exposure to BG00010.